FDA estrogen guidance
Executive Summary
Agency will hold a meeting in December concerning hormone therapy draft guidance revisions. FDA may release a revised guidance in 2006 including methods for determining the lowest effective dose in estrogen replacement drug products. Agency will revise guidance to refine changes resulting from safety signals in the NIH Women's Health Initiative hormone therapy trial (1"The Pink Sheet" May 16, 2005, p. 21)...
You may also be interested in...
Estrogen Products Guidance To Be Revised; FDA Will Outline Plans In June
FDA will make significant changes to a 2003 FDL-1draft guidance on estrogen products and reissue a new draft
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.